1. Regulatory Complexity and Approval Pathways
Combination products, such as drug-device or biologic-device products, often face complex regulatory pathways because they involve multiple components regulated under different frameworks. Manufacturers must determine the product’s primary mode of action (PMOA) to identify which regulatory center will oversee approval. Differences in global regulations can further delay market entry and increase compliance costs.
Example: An insulin pen combines a drug (insulin) and a delivery device, requiring review of both pharmaceutical safety and device functionality before approval.
2. Product Development and Technical Integration
Developing combination products requires close coordination between engineering, pharmaceutical, and clinical teams. Challenges arise in ensuring that all components work together safely without affecting performance or stability. Compatibility testing, human factor studies, and manufacturing consistency are essential before launch.
Example: A drug-eluting stent must release medication at a controlled rate while maintaining the mechanical strength needed to keep an artery open.
3. Resource and Operational Demands
Combination products require significant human and technical resources, including regulatory experts, quality assurance teams, and specialized manufacturing facilities. Companies may struggle with supply chain coordination when components come from different vendors. Managing cross-functional teams can also slow decision-making and increase project complexity.
Example: A company producing a prefilled syringe may need separate suppliers for the syringe, injectable drug, packaging materials, and sterilization services.
4. Financial Risk and Commercialization Challenges
The cost of bringing combination products to market is often higher than for single-component products due to research, testing, and regulatory requirements. Reimbursement uncertainty, pricing pressures, and market competition can make it difficult to recover investment. Companies must carefully assess whether the product offers enough clinical value to justify the expense.
Example: A wearable insulin pump may require millions in development costs, but limited insurance reimbursement could reduce patient access and lower profitability.
